Inflammatory memory in psoriasis: From remission to recurrence

J Allergy Clin Immunol. 2024 Jul;154(1):42-50. doi: 10.1016/j.jaci.2024.05.008. Epub 2024 May 17.

Abstract

The routine use of targeted systemic immunomodulatory therapies has transformed outcomes for people with severe psoriasis, with skin clearance (clinical remission) rates up to 60% at 1 year of biologic treatment. However, psoriasis may recur following drug withdrawal, and as a result, patients tend to continue receiving costly treatment indefinitely. Here, we review research into the "inflammatory memory" in resolved psoriasis skin and the potential mechanisms leading to psoriasis recurrence following drug withdrawal. Research has implicated immune cells such as tissue resident memory T cells, Langerhans cells, and dermal dendritic cells, and there is growing interest in keratinocytes and fibroblasts. A better understanding of the interactions between these cell populations, enabled by single cell technologies, will help to elucidate the events underpinning the shift from remission to recurrence. This may inform the development of personalized strategies for sustaining remission while reducing long-term drug burden.

Keywords: Inflammatory memory; epigenetics; psoriasis; recurrence; remission; single cell technology; tissue resident memory T cell.

Publication types

  • Review

MeSH terms

  • Animals
  • Humans
  • Immunologic Memory*
  • Inflammation / immunology
  • Psoriasis* / drug therapy
  • Psoriasis* / immunology
  • Recurrence*
  • Remission Induction
  • Skin / immunology
  • Skin / pathology